Page 11 - Pharma Companies
Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore
Aurobindo's stock reacted positively to the news, going up in morning trade but later settled flat at Rs 784.65 on the BSE
 "Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore")
Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity
The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.
 "Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity")
Strong prospects of Biologics business keep Street positive on Biocon
Even though Q2 performance missed estimates, analysts expect a stronger second half
 "Strong prospects of Biologics business keep Street positive on Biocon")
Oxford Covid-19 vaccine doing everything expected', independent study finds
The experts say that the novel analysis provides even greater clarity and detail about how the vaccine successfully provokes a strong immune response.
 "Oxford Covid-19 vaccine doing everything expected', independent study finds")
Roche Holding sales disappoint as drugs decline eclipses Covid-19 tests
The Swiss drugmaker's revenue rose 1% to 14.7 billion francs ($16.1 billion), the company said
 "Roche Holding sales disappoint as drugs decline eclipses Covid-19 tests")
3 firms get clinical trial approval for alternative Covid-19 drugs
The drug 2-DG is not yet an approved drug, but there have been multiple studies across the globe for treatment of cancers
 "3 firms get clinical trial approval for alternative Covid-19 drugs")
Smaller pharma firms post faster domestic sales growth in September
Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth
 "Smaller pharma firms post faster domestic sales growth in September")
PE/VC investments in pharma companies grow 3.5X in 2020, cross $1 bn mark
The reputation and relationships have helped pharma industry raise huge amounts of PE capital in 2020.
 "PE/VC investments in pharma companies grow 3.5X in 2020, cross $1 bn mark")
Patented molecules clock a high growth rate in Indian cardiovascular market
In January 2020, the Delhi High Court granted an injunction restraining domestic companies such as Cipla, Torrent, Emcure, and Alkem from launching their brands
 "Patented molecules clock a high growth rate in Indian cardiovascular market")
Revised, more industry-friendly PLI scheme for bulk drugs on the cards
Industry says move will mean lower spends and reduced dependence on China
 "Revised, more industry-friendly PLI scheme for bulk drugs on the cards")
Credit metrics of leading pharma companies to remain stable: ICRA
The global demand scenario for Indian pharmaceutical industry is largely expected to remain stable due to inelastic nature of prescription drugs, investment information agency ICRA has said.
 "Credit metrics of leading pharma companies to remain stable: ICRA")
Syngene: Investors with long term view should look at the stock on dips
While Covid-19 could is a near term opportunity, contract manufacturing is the key medium-term trigger
 "Syngene: Investors with long term view should look at the stock on dips")
Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US
According to IQVIA MAT July 2020 data, Divalproex Sodium extended-release tablets USP had annual sales of approximately USD 130 million (about Rs 950 crore) in the US
 "Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US")
Gilead nears deal to buy Immunomedics for more than $20 billion: Report
Discussions between Gilead and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation
Gilead nears deal to buy Immunomedics for more than $20 bn: WSJ report
Gilead Sciences Inc is said to be nearing a deal to buy biopharmaceutical company Immunomedics Incfor more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments
 "Gilead nears deal to buy Immunomedics for more than $20 bn: WSJ report")
BPPI Q1 sales turnover up 94.21% to Rs 146.59 cr amid Covid-19 crisis
It had posted a sales turnover of Rs 75.48 crore in the corresponding first quarter of previous fiscal year, a statement by the ministry said
Remdesivir prices may rise after Gilead gets full authorisation from USFDA
In August, Gilead filed an application with the US Food and Drug Administration (USFDA) seeking full approval for remdesivir (Veklury)
 "Remdesivir prices may rise after Gilead gets full authorisation from USFDA")
Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%
As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated
 "Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%")
Pharmacy consolidation may disrupt domestic drug market: Credit Suisse
The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more
 "Pharmacy consolidation may disrupt domestic drug market: Credit Suisse")
National Expert Group meets Covid-19 vaccine makers to discuss road ahead
Representatives from Serum Institute of India, Bharat Biotech, Zydus Cadila, Gennova Biopharmaceuticals and Biological E met the expert group that is chaired by NITI member Vinod K Paul
 "National Expert Group meets Covid-19 vaccine makers to discuss road ahead")
